Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection

J. S. Young, J. Chen, M. L. Miller, V. Vu, C. Tian, J. J. Moon, M. L. Alegre, Roger Sciammas, A. S. Chong

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Antibody-mediated rejection has emerged as the leading cause of late graft loss in kidney transplant recipients, and inhibition of donor-specific antibody production should lead to improved transplant outcomes. The fusion protein cytotoxic T lymphocyte–associated protein 4–immunoglobulin (CTLA4-Ig) blocks T cell activation and consequently inhibits T-dependent B cell antibody production, and the current paradigm is that CTLA4-Ig is effective with naïve T cells and less so with activated or memory T cells. In this study, we used a mouse model of allosensitization to investigate the efficacy of continuous CTLA4-Ig treatment, initiated 7 or 14 days after sensitization, for inhibiting ongoing allospecific B cell responses. Delayed treatment with CTLA4-Ig collapsed the allospecific germinal center B cell response and inhibited alloantibody production. Using adoptively transferred T cell receptor transgenic T cells and a novel approach to track endogenous graft-specific T cells, we demonstrate that delayed CTLA4-Ig minimally inhibited graft-specific CD4+ and T follicular helper responses. Remarkably, delaying CTLA4-Ig until day 6 after transplantation in a fully mismatched heart transplant model inhibited alloantibody production and prevented acute rejection, whereas transferred hyperimmune sera reversed the effects of delayed CTLA4-Ig. Collectively, our studies revealed the unexpected efficacy of CTLA4-Ig for inhibiting ongoing B cell responses even when the graft-specific T cell response was robustly established.

Original languageEnglish (US)
Pages (from-to)2312-2323
Number of pages12
JournalAmerican Journal of Transplantation
Volume16
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Isoantibodies
Allografts
T-Lymphocytes
Transplants
Proteins
B-Lymphocytes
Therapeutics
Antibody Formation
Germinal Center
T-Cell Antigen Receptor
Transplantation
Tissue Donors
Kidney
Antibodies

Keywords

  • alloantibody
  • animal models: murine
  • B cell biology
  • basic (laboratory) research/science
  • fusion proteins and monoclonal antibodies: belatacept
  • immunobiology
  • immunosuppressant
  • immunosuppression/immune modulation
  • immunosuppressive regimens
  • organ transplantation in general
  • rescue

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. / Young, J. S.; Chen, J.; Miller, M. L.; Vu, V.; Tian, C.; Moon, J. J.; Alegre, M. L.; Sciammas, Roger; Chong, A. S.

In: American Journal of Transplantation, Vol. 16, No. 8, 01.08.2016, p. 2312-2323.

Research output: Contribution to journalArticle

Young, J. S. ; Chen, J. ; Miller, M. L. ; Vu, V. ; Tian, C. ; Moon, J. J. ; Alegre, M. L. ; Sciammas, Roger ; Chong, A. S. / Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 8. pp. 2312-2323.
@article{66b06c416b1b40e592131ff8dfffc58c,
title = "Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection",
abstract = "Antibody-mediated rejection has emerged as the leading cause of late graft loss in kidney transplant recipients, and inhibition of donor-specific antibody production should lead to improved transplant outcomes. The fusion protein cytotoxic T lymphocyte–associated protein 4–immunoglobulin (CTLA4-Ig) blocks T cell activation and consequently inhibits T-dependent B cell antibody production, and the current paradigm is that CTLA4-Ig is effective with na{\"i}ve T cells and less so with activated or memory T cells. In this study, we used a mouse model of allosensitization to investigate the efficacy of continuous CTLA4-Ig treatment, initiated 7 or 14 days after sensitization, for inhibiting ongoing allospecific B cell responses. Delayed treatment with CTLA4-Ig collapsed the allospecific germinal center B cell response and inhibited alloantibody production. Using adoptively transferred T cell receptor transgenic T cells and a novel approach to track endogenous graft-specific T cells, we demonstrate that delayed CTLA4-Ig minimally inhibited graft-specific CD4+ and T follicular helper responses. Remarkably, delaying CTLA4-Ig until day 6 after transplantation in a fully mismatched heart transplant model inhibited alloantibody production and prevented acute rejection, whereas transferred hyperimmune sera reversed the effects of delayed CTLA4-Ig. Collectively, our studies revealed the unexpected efficacy of CTLA4-Ig for inhibiting ongoing B cell responses even when the graft-specific T cell response was robustly established.",
keywords = "alloantibody, animal models: murine, B cell biology, basic (laboratory) research/science, fusion proteins and monoclonal antibodies: belatacept, immunobiology, immunosuppressant, immunosuppression/immune modulation, immunosuppressive regimens, organ transplantation in general, rescue",
author = "Young, {J. S.} and J. Chen and Miller, {M. L.} and V. Vu and C. Tian and Moon, {J. J.} and Alegre, {M. L.} and Roger Sciammas and Chong, {A. S.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1111/ajt.13761",
language = "English (US)",
volume = "16",
pages = "2312--2323",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Delayed Cytotoxic T Lymphocyte–Associated Protein 4–Immunoglobulin Treatment Reverses Ongoing Alloantibody Responses and Rescues Allografts From Acute Rejection

AU - Young, J. S.

AU - Chen, J.

AU - Miller, M. L.

AU - Vu, V.

AU - Tian, C.

AU - Moon, J. J.

AU - Alegre, M. L.

AU - Sciammas, Roger

AU - Chong, A. S.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Antibody-mediated rejection has emerged as the leading cause of late graft loss in kidney transplant recipients, and inhibition of donor-specific antibody production should lead to improved transplant outcomes. The fusion protein cytotoxic T lymphocyte–associated protein 4–immunoglobulin (CTLA4-Ig) blocks T cell activation and consequently inhibits T-dependent B cell antibody production, and the current paradigm is that CTLA4-Ig is effective with naïve T cells and less so with activated or memory T cells. In this study, we used a mouse model of allosensitization to investigate the efficacy of continuous CTLA4-Ig treatment, initiated 7 or 14 days after sensitization, for inhibiting ongoing allospecific B cell responses. Delayed treatment with CTLA4-Ig collapsed the allospecific germinal center B cell response and inhibited alloantibody production. Using adoptively transferred T cell receptor transgenic T cells and a novel approach to track endogenous graft-specific T cells, we demonstrate that delayed CTLA4-Ig minimally inhibited graft-specific CD4+ and T follicular helper responses. Remarkably, delaying CTLA4-Ig until day 6 after transplantation in a fully mismatched heart transplant model inhibited alloantibody production and prevented acute rejection, whereas transferred hyperimmune sera reversed the effects of delayed CTLA4-Ig. Collectively, our studies revealed the unexpected efficacy of CTLA4-Ig for inhibiting ongoing B cell responses even when the graft-specific T cell response was robustly established.

AB - Antibody-mediated rejection has emerged as the leading cause of late graft loss in kidney transplant recipients, and inhibition of donor-specific antibody production should lead to improved transplant outcomes. The fusion protein cytotoxic T lymphocyte–associated protein 4–immunoglobulin (CTLA4-Ig) blocks T cell activation and consequently inhibits T-dependent B cell antibody production, and the current paradigm is that CTLA4-Ig is effective with naïve T cells and less so with activated or memory T cells. In this study, we used a mouse model of allosensitization to investigate the efficacy of continuous CTLA4-Ig treatment, initiated 7 or 14 days after sensitization, for inhibiting ongoing allospecific B cell responses. Delayed treatment with CTLA4-Ig collapsed the allospecific germinal center B cell response and inhibited alloantibody production. Using adoptively transferred T cell receptor transgenic T cells and a novel approach to track endogenous graft-specific T cells, we demonstrate that delayed CTLA4-Ig minimally inhibited graft-specific CD4+ and T follicular helper responses. Remarkably, delaying CTLA4-Ig until day 6 after transplantation in a fully mismatched heart transplant model inhibited alloantibody production and prevented acute rejection, whereas transferred hyperimmune sera reversed the effects of delayed CTLA4-Ig. Collectively, our studies revealed the unexpected efficacy of CTLA4-Ig for inhibiting ongoing B cell responses even when the graft-specific T cell response was robustly established.

KW - alloantibody

KW - animal models: murine

KW - B cell biology

KW - basic (laboratory) research/science

KW - fusion proteins and monoclonal antibodies: belatacept

KW - immunobiology

KW - immunosuppressant

KW - immunosuppression/immune modulation

KW - immunosuppressive regimens

KW - organ transplantation in general

KW - rescue

UR - http://www.scopus.com/inward/record.url?scp=84978833967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978833967&partnerID=8YFLogxK

U2 - 10.1111/ajt.13761

DO - 10.1111/ajt.13761

M3 - Article

VL - 16

SP - 2312

EP - 2323

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -